However, multiple recent studies have shown an oncogenic effect of KDM6B overexpression in hematologic malignancies, including MDS (34), AML (35), multiple myeloma (36), and lymphoid malignancies (37–39). Here, KDM6B is linked to acute myeloid leukemia.